KR100667367B1 - 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법 - Google Patents
용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법 Download PDFInfo
- Publication number
- KR100667367B1 KR100667367B1 KR1020050038684A KR20050038684A KR100667367B1 KR 100667367 B1 KR100667367 B1 KR 100667367B1 KR 1020050038684 A KR1020050038684 A KR 1020050038684A KR 20050038684 A KR20050038684 A KR 20050038684A KR 100667367 B1 KR100667367 B1 KR 100667367B1
- Authority
- KR
- South Korea
- Prior art keywords
- cilostazol
- nicotinamide
- complex
- prepared
- preparing
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Abstract
Description
Claims (8)
- 삭제
- 삭제
- 실로스타졸과 니코틴아미드 1 : 1 내지 10 몰비의 혼합물을 110℃ 내지 200℃로 용융시키고 교반한 후 냉각시켜 제조된 것을 특징으로 하는 실로스타졸-니코틴아미드 복합체.
- 삭제
- 삭제
- 삭제
- 제 3항에 있어서,상기 복합체의 실로스타졸은 결정형 C형인 것을 특징으로 하는 실로스타졸-니코틴아미드 복합체.
- 제 3항 또는 제 7항에 따른 실로스타졸-니코틴아미드 복합체를 함유하는 혈소판 응집 억제용 의약조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050038684A KR100667367B1 (ko) | 2005-05-10 | 2005-05-10 | 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법 |
PCT/KR2006/001638 WO2006121249A1 (en) | 2005-05-10 | 2006-05-02 | Cilostazol composite having increasing solubility, process for preparation and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050038684A KR100667367B1 (ko) | 2005-05-10 | 2005-05-10 | 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060116422A KR20060116422A (ko) | 2006-11-15 |
KR100667367B1 true KR100667367B1 (ko) | 2007-01-10 |
Family
ID=37396726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050038684A KR100667367B1 (ko) | 2005-05-10 | 2005-05-10 | 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100667367B1 (ko) |
WO (1) | WO2006121249A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050101631A1 (en) | 2002-08-01 | 2005-05-12 | Otsuka Pharmaceuticals Company | Process for producing carbostyril derivatives |
CN102933205B (zh) * | 2010-04-28 | 2014-08-13 | 诺弗米克斯有限公司 | 西洛他唑共晶和组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EG23951A (en) * | 1999-03-25 | 2008-01-29 | Otsuka Pharma Co Ltd | Cilostazol preparation |
JP2003063965A (ja) * | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
-
2005
- 2005-05-10 KR KR1020050038684A patent/KR100667367B1/ko active IP Right Grant
-
2006
- 2006-05-02 WO PCT/KR2006/001638 patent/WO2006121249A1/en active Application Filing
Non-Patent Citations (2)
Title |
---|
1020050038684 - 714322 * |
논문 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006121249A1 (en) | 2006-11-16 |
KR20060116422A (ko) | 2006-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102354963B1 (ko) | N-{4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐}-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법 | |
JP5934204B2 (ja) | C−met調節剤の薬学的組成物 | |
JP6211072B2 (ja) | ダサチニブと、選択された共結晶形成剤とを含んでなる多成分結晶 | |
CA2854549C (en) | Ivabradine hydrochloride form iv | |
JP6034789B2 (ja) | 結晶性ナロキソール−peg接合体 | |
WO2008040816A1 (en) | Amorphous asenapine and processes for preparing same | |
JP2020521003A (ja) | 重水素化azd9291の結晶形、製造方法および使用 | |
CN110128356A (zh) | 一种吉非替尼与3-羟基苯甲酸共晶体 | |
JP6849804B2 (ja) | ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途 | |
CN109400598B (zh) | 盐酸小檗碱与乳酸共晶、其制备方法和应用 | |
CN112047893A (zh) | 吉非替尼与水杨酸共晶体 | |
WO2010060387A1 (zh) | 硝克柳胺化合物五种晶型、其制法和其药物组合物与用途 | |
CN103476742A (zh) | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 | |
KR100667367B1 (ko) | 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법 | |
WO2023193563A1 (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
CN103476743A (zh) | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 | |
WO2012114325A1 (en) | Polymorphs of asenapine maleate | |
CN109311820A (zh) | 2,6-二甲基嘧啶酮衍生物的盐及其用途 | |
CN113354621B (zh) | 1-取代苄基-3-芳基脲类化合物及其制备方法和应用 | |
Blokhina et al. | New diclofenac choline hydrate salt: Synthesis, characterization and solubility | |
Xiong et al. | Effects of temperature and solvent on the solid-state transformations of pranlukast during mechanical milling | |
Xu et al. | Polymorphs and amorphous state of glipizide: preparation and solid-state transformations | |
EP2681212A1 (en) | Crystalline compound comprising tiotropium bromide | |
CN113292484A (zh) | 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用 | |
de Oliveira Junior et al. | A New Crystalline Ketoprofen Sodium Salt: Solid-State Characterization, Solubility, and Stability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20111129 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140102 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150102 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151229 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161227 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20191231 Year of fee payment: 14 |